Biovaxys Technology Corp (BVAXF)

$0.07 -0.01 (-12.55%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 15,900
Avg Vol 27,200
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 18%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. It also provides Maveropepimut-S (MVP-S), which has completed phase IIb clinical trial for advanced Relapsed-Refractory Diffuse Large B Cell...

Industry: Biotechnology
Sector: Healthcare
Phone: 740-358-0555
Address:
146 Thirtieth Street, Suite 100, Etobicoke, Canada
wheresdannynow
wheresdannynow Aug. 12 at 6:56 PM
$BVAXF Quality people, quality data, and the platform keeps getting noticed despite the trading pause.
0 · Reply
wheresdannynow
wheresdannynow Aug. 12 at 6:56 PM
$BVAXF This is exactly the kind of independent signal that matters. BioVaxys’ PI on the PESCO ovarian study just took home the 2026 IGCS Lifetime Achievement Award.
0 · Reply
wheresdannynow
wheresdannynow Aug. 12 at 6:55 PM
$BVAXF Dr. Oza getting the IGCS Lifetime Achievement Award for work that includes the PESCO trial with MVP-S
0 · Reply
ProfitWhisperer
ProfitWhisperer Aug. 12 at 4:51 PM
$BVAXF $BIOV.CSE Dr. Oza receiving IGCS Lifetime Achievement Award validates the clinical leadership running DPX trials. PESCO study with MVP-S advancing. Platform earning credibility from the people who matter. Aug 19 validation checkpoint coming. https://x.com/biovaxys/status/2087312269768073376
0 · Reply
FLArnot
FLArnot Aug. 12 at 1:14 AM
$BVAXF Down over 55% over one year.
0 · Reply
FLArnot
FLArnot Aug. 12 at 1:13 AM
$BVAXF No update from management on CTO.
0 · Reply
FLArnot
FLArnot Aug. 12 at 1:12 AM
$BVAXF Cease Trade Order for over a full quarter of year.
0 · Reply
Ventureville
Ventureville Aug. 11 at 6:17 PM
$BVAXF Saw the CSE notice ending mandatory Form 7s; one less administrative item for issuers.
0 · Reply
Ventureville
Ventureville Aug. 11 at 6:17 PM
$BVAXF CSE dropping Form 7s is interesting, but yeah the filing delay and halt have dragged way too long. Still waiting on that actual status update.
0 · Reply
Ventureville
Ventureville Aug. 11 at 6:16 PM
$BVAXF CSE simplifying rules by ditching monthly Form 7s is a small positive for the exchange. Now if BioVaxys can just clear the overdue filings and lift the halt, the underlying DPX tech and earlier positive readouts in ovarian/bladder get a chance to drive the conversation again.
0 · Reply
Latest News on BVAXF
No data available.
wheresdannynow
wheresdannynow Aug. 12 at 6:56 PM
$BVAXF Quality people, quality data, and the platform keeps getting noticed despite the trading pause.
0 · Reply
wheresdannynow
wheresdannynow Aug. 12 at 6:56 PM
$BVAXF This is exactly the kind of independent signal that matters. BioVaxys’ PI on the PESCO ovarian study just took home the 2026 IGCS Lifetime Achievement Award.
0 · Reply
wheresdannynow
wheresdannynow Aug. 12 at 6:55 PM
$BVAXF Dr. Oza getting the IGCS Lifetime Achievement Award for work that includes the PESCO trial with MVP-S
0 · Reply
ProfitWhisperer
ProfitWhisperer Aug. 12 at 4:51 PM
$BVAXF $BIOV.CSE Dr. Oza receiving IGCS Lifetime Achievement Award validates the clinical leadership running DPX trials. PESCO study with MVP-S advancing. Platform earning credibility from the people who matter. Aug 19 validation checkpoint coming. https://x.com/biovaxys/status/2087312269768073376
0 · Reply
FLArnot
FLArnot Aug. 12 at 1:14 AM
$BVAXF Down over 55% over one year.
0 · Reply
FLArnot
FLArnot Aug. 12 at 1:13 AM
$BVAXF No update from management on CTO.
0 · Reply
FLArnot
FLArnot Aug. 12 at 1:12 AM
$BVAXF Cease Trade Order for over a full quarter of year.
0 · Reply
Ventureville
Ventureville Aug. 11 at 6:17 PM
$BVAXF Saw the CSE notice ending mandatory Form 7s; one less administrative item for issuers.
0 · Reply
Ventureville
Ventureville Aug. 11 at 6:17 PM
$BVAXF CSE dropping Form 7s is interesting, but yeah the filing delay and halt have dragged way too long. Still waiting on that actual status update.
0 · Reply
Ventureville
Ventureville Aug. 11 at 6:16 PM
$BVAXF CSE simplifying rules by ditching monthly Form 7s is a small positive for the exchange. Now if BioVaxys can just clear the overdue filings and lift the halt, the underlying DPX tech and earlier positive readouts in ovarian/bladder get a chance to drive the conversation again.
0 · Reply
ProfitWhisperer
ProfitWhisperer Aug. 11 at 5:35 PM
$BVAXF $BIOV.CSE Aug 19 matters because it's a DoD panel evaluating BIOV/Sona acral melanoma work, separate from BIOV's own narrative. External validation happening while the halt sits. Platform gets credibility from people with zero financial exposure to the stock.
0 · Reply
Davidendz
Davidendz Aug. 10 at 5:32 PM
$BVAXF Hoping the next update finally moves things forward so the platform can be evaluated on its merits again.
0 · Reply
Davidendz
Davidendz Aug. 10 at 5:32 PM
$BVAXF Still no official word on the delayed filings or when trading resumes, that’s the reality right now.
0 · Reply
Davidendz
Davidendz Aug. 10 at 5:31 PM
$BVAXF Anyone catch any new news? Still waiting on that update so we can get trading back and focus on the actual pipeline.
0 · Reply
ProfitWhisperer
ProfitWhisperer Aug. 10 at 4:46 PM
$BVAXF $BIOV.CSE DoD FY2026 Melanoma Research Program reviewing BIOV/Sona acral melanoma work. Aug 19 notification if invited to full application. Third-party validation independent of halt status. Platform gets vetted by people with zero stake in stock. Filing completion unlocks trading. Science already earning credibility.
0 · Reply
wheresdannynow
wheresdannynow Aug. 7 at 6:04 PM
$BVAXF Still no official word on the delayed filings or when trading resumes; that’s the reality right now.
0 · Reply
wheresdannynow
wheresdannynow Aug. 7 at 6:04 PM
$BVAXF The halt’s gone on long enough, once the filings clear and shares resume, the DPX platform and those earlier clinical responses should get proper attention again.
1 · Reply
wheresdannynow
wheresdannynow Aug. 7 at 6:03 PM
$BVAXF Heard any whispers of an update yet?
0 · Reply
ProfitWhisperer
ProfitWhisperer Aug. 7 at 3:50 PM
$BVAXF $BIOV.CSE DPX platform already validated with durable T-cell responses in multiple indications. Halt and silence are real frustrations. But once trading resumes, market can price what's already proven. Science conversation takes over.
0 · Reply
Davidendz
Davidendz Aug. 6 at 3:41 PM
$BVAXF this is still a platform company with DPX tech that has already shown durable T-cell responses in multiple indications
0 · Reply
Davidendz
Davidendz Aug. 6 at 3:40 PM
$BVAXF The silence and extended halt suck, no question.
0 · Reply
Davidendz
Davidendz Aug. 6 at 3:40 PM
$BVAXF Once trading is restored, the real value conversation can start again.
0 · Reply